Alumis Inc. (NASDAQ:ALMS) Major Shareholder Purchases $115,500.00 in Stock

Alumis Inc. (NASDAQ:ALMS) major shareholder Foresite Labs, Llc bought 25,000 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The stock was purchased at an average price of $4.62 per share, for a total transaction of $115,500.00. Following the acquisition, the insider now directly owns 4,227,670 shares in the company, valued at approximately $19,531,835.40. This trade represents a 0.59 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Foresite Labs, Llc also recently made the following trade(s):

• On Tuesday, May 6th, Foresite Labs, Llc acquired 20,000 shares of Alumis stock. The stock was acquired at an average price of $4.34 per share, for a total transaction of $86,800.00.

Alumis Stock Down 5.5 %

Shares of ALMS stock opened at $5.03 on Friday. Alumis Inc. has a one year low of $3.18 and a one year high of $13.53. The stock has a fifty day moving average price of $5.43 and a 200 day moving average price of $7.21.

Hedge Funds Weigh In On Alumis

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its stake in Alumis by 12.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 127,854 shares of the company’s stock valued at $785,000 after acquiring an additional 14,453 shares during the period. BML Capital Management LLC bought a new stake in shares of Alumis in the 1st quarter valued at approximately $305,000. Towerview LLC grew its stake in shares of Alumis by 3.6% in the 1st quarter. Towerview LLC now owns 430,000 shares of the company’s stock valued at $2,640,000 after purchasing an additional 15,000 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Alumis by 37.0% in the 1st quarter. Bank of New York Mellon Corp now owns 42,403 shares of the company’s stock worth $260,000 after buying an additional 11,453 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Alumis by 21.7% during the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after buying an additional 2,949 shares during the period.

Wall Street Analysts Forecast Growth

ALMS has been the topic of a number of research analyst reports. Oppenheimer initiated coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Alumis in a research note on Wednesday, April 30th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Alumis currently has an average rating of “Buy” and a consensus target price of $25.86.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.